Evidence map›Paper›PMID 35661214›Full record

Trial reportThe Journal of clinical endocrinology and metabolism2022

Six-Month Periodic Fasting in Patients With Type 2 Diabetes and Diabetic Nephropathy: A Proof-of-Concept Study.

Alba Sulaj, Stefan Kopf, Ekaterina von Rauchhaupt, Elisabeth Kliemank, Maik Brune, Zoltan Kender, Hannelore Bartl, Fabiola Garcia Cortizo, Katarina Klepac, Zhe Han and 9 more

Registry-linked trialOpen access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Journal of clinical endocrinology and metabolism, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06518798 (Pilot Study on Fasting-Mimicking Diet in Asian Americans With Prediabetes), which is not on this map. Cited by 30 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 2 pooled it
6.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06518798 nacompletednot on this mapstarted 2024, after this paper: background citation

Pilot Study on Fasting-Mimicking Diet in Asian Americans With Prediabetes

TypeinterventionalSponsorUniversity of California, IrvineRan2024 to 2025Enrolled30ConditionsPrediabetes, Prediabetic StateArmsFasting Mimicking Diet
3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 57 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Review
  10. Review
  11. Article
  12. Nutritional and Fasting Strategies for the Management of MASLD/MASH: An Integrative Review.JGH open : an open access journal of gastroenterology and hepatology · 2025
    Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 3 institutions in 3 countries.

Alba SulajDepartment of Endocrinology, Diabetology, Metabolism and Clinical Chemistry (Internal Medicine 1), Heidelberg University Hospital, Heidelberg, Germany.ORCID 0000-0002-6051-6696
Stefan KopfDepartment of Endocrinology, Diabetology, Metabolism and Clinical Chemistry (Internal Medicine 1), Heidelberg University Hospital, Heidelberg, Germany.
Ekaterina von RauchhauptDepartment of Endocrinology, Diabetology, Metabolism and Clinical Chemistry (Internal Medicine 1), Heidelberg University Hospital, Heidelberg, Germany.
Elisabeth KliemankDepartment of Endocrinology, Diabetology, Metabolism and Clinical Chemistry (Internal Medicine 1), Heidelberg University Hospital, Heidelberg, Germany.
Maik BruneDepartment of Endocrinology, Diabetology, Metabolism and Clinical Chemistry (Internal Medicine 1), Heidelberg University Hospital, Heidelberg, Germany.
Zoltan KenderDepartment of Endocrinology, Diabetology, Metabolism and Clinical Chemistry (Internal Medicine 1), Heidelberg University Hospital, Heidelberg, Germany.
Hannelore BartlDepartment of Endocrinology, Diabetology, Metabolism and Clinical Chemistry (Internal Medicine 1), Heidelberg University Hospital, Heidelberg, Germany.
Fabiola Garcia CortizoGerman Cancer Research Center (DKFZ), Division of Signal Transduction in Cancer and Metabolism, Heidelberg, Germany.
Katarina KlepacInstitute for Diabetes and Cancer, Helmholtz Center Munich, Neuherberg, Germany.
Zhe HanDepartment of Endocrinology, Diabetology, Metabolism and Clinical Chemistry (Internal Medicine 1), Heidelberg University Hospital, Heidelberg, Germany.
Varun KumarDepartment of Endocrinology, Diabetology, Metabolism and Clinical Chemistry (Internal Medicine 1), Heidelberg University Hospital, Heidelberg, Germany.
Valter LongoLongevity Institute, School of Gerontology, and Department of Biological Sciences, University of Southern California, Los Angeles, CA, USA.
Aurelio TelemanGerman Cancer Research Center (DKFZ), Division of Signal Transduction in Cancer and Metabolism, Heidelberg, Germany.
Jürgen G OkunDepartment of General Pediatrics, Division of Neuropediatrics and Metabolic Medicine, Centre for Pediatric and Adolescent Medicine, University Hospital Heidelberg, Heidelberg, Germany.
Jakob MorgensternDepartment of Endocrinology, Diabetology, Metabolism and Clinical Chemistry (Internal Medicine 1), Heidelberg University Hospital, Heidelberg, Germany.
Thomas FlemingDepartment of Endocrinology, Diabetology, Metabolism and Clinical Chemistry (Internal Medicine 1), Heidelberg University Hospital, Heidelberg, Germany.
Julia SzendroediDepartment of Endocrinology, Diabetology, Metabolism and Clinical Chemistry (Internal Medicine 1), Heidelberg University Hospital, Heidelberg, Germany.
Stephan HerzigGerman Center of Diabetes Research (DZD), Neuherberg, Germany.
Peter P NawrothDepartment of Endocrinology, Diabetology, Metabolism and Clinical Chemistry (Internal Medicine 1), Heidelberg University Hospital, Heidelberg, Germany.
Heidelberg University · DEGerman Cancer Research Center · DEUniversity of Southern California · US

Funding

Deutsche Forschungsgemeinschaft 236360313-SFB 1118Deutsches Zentrum für DiabetesforschungDiabetes Research 82DZD07C2GGerman Research Foundation 236360313-SFB 1118
6 · The paper itself

Abstract

contextNovel fasting interventions have gained scientific and public attention. Periodic fasting has emerged as a dietary modification promoting beneficial effects on metabolic syndrome.

objectiveAssess whether periodic fasting reduces albuminuria and activates nephropathy-driven pathways. DESIGN/

participantsProof-of-concept study where individuals with type 2 diabetes (n = 40) and increased albumin-to-creatinine ratio (ACR) were randomly assigned to receive a monthly fasting-mimicking diet (FMD) or a Mediterranean diet for 6 months with 3-month follow-up. MAIN OUTCOMES MEASURES: Change in ACR was assessed by analysis of covariance adjusted for age, sex, weight loss, and baseline value. Prespecified subgroup analysis for patients with micro- vs macroalbuminuria at baseline was performed. Change in homeostatic model assessment for insulin resistance (HOMA-IR), circulating markers of dicarbonyl detoxification (methylglyoxal-derived hydroimidazolone 1, glyoxalase-1, and hydroxyacetone), DNA-damage/repair (phosphorylated histone H2AX), lipid oxidation (acylcarnitines), and senescence (soluble urokinase plasminogen activator receptor) were assessed as exploratory endpoints.

resultsFMD was well tolerated with 71% to 95% of the participants reporting no adverse effects. After 6 months, change in ACR was comparable between study groups [110.3 (99.2, 121.5) mg/g; P = 0.45]. FMD led to a reduction of ACR in patients with microalbuminuria levels at baseline [-30.3 (-35.7, -24.9) mg/g; P ≤ 0.05] but not in those with macroalbuminuria [434.0 (404.7, 463.4) mg/g; P = 0.23]. FMD reduced HOMA-IR [-3.8 (-5.6, -2.0); P ≤ 0.05] and soluble urokinase plasminogen activator receptor [-156.6 (-172.9, -140.4) pg/mL; P ≤ 0.05], while no change was observed in markers of dicarbonyl detoxification or DNA-damage/repair. Change in acylcarnitines was related to patient responsiveness to ACR improvement. At follow-up only HOMA-IR reduction [-1.9 (-3.7, -0.1), P ≤ 0.05]) was sustained.

conclusionsImprovement of microalbuminuria and of markers of insulin resistance, lipid oxidation, and senescence suggest the potential beneficial effects of periodic fasting in type 2 diabetes.

Indexed as

Diabetes Mellitus, Type 2Diabetic NephropathiesInsulin ResistanceAlbuminuriaBiomarkersCreatinineDNAFastingHumansLipidsReceptors, Urokinase Plasminogen ActivatorBiomarkersCreatinineDNALipidsReceptors, Urokinase Plasminogen Activatordiabetic nephropathydicarbonyl detoxificationinsulin resistancelipid oxidationperiodic fastingsenescence

Identifiers

PMID35661214
PMCPMC9282263
OpenAlexW4281696305

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.